Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS-siRNA TPN
- Development stage
- Preclinical
- Lead developer
- Massachusetts Institute of Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
KRAS-siRNA TPN is a preclinical-stage therapeutic candidate consisting of small interfering RNA (siRNA) targeting the KRAS oncogene, encapsulated within tumor-penetrating nanoparticles (TPNs). Developed at MIT, the TPN platform utilizes tandem tumor-penetrating and membrane-translocating peptides to facilitate deep penetration into the dense stroma of pancreatic ductal adenocarcinoma (PDAC) and ensure cytosolic delivery of the siRNA. By silencing KRAS expression, the drug aims to inhibit the primary driver of pancreatic cancer growth. In vivo studies in murine PDAC models have shown that systemic administration of KRAS-siRNA TPNs can effectively suppress tumor progression.
- Other names
- KRAS-specific TPNstumor-penetrating nanoparticles carrying KRAS siRNA
02
Targets
NRP1 (Neuropilin-1)Kirsten rat sarcoma viral oncogene homolog mRNAαVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on KRAS-siRNA TPN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS-siRNA TPN.